Mulder E J H, Koenen S V, Blom I, Visser G H A
Department of Perinatology and Gynaecology, Wilhelmina Children's Hospital, University Medical Centre, KE.04.123.1, Lundlaan 6, 3584 EA Utrecht, The Netherlands.
Early Hum Dev. 2004 Jan;76(1):65-77. doi: 10.1016/j.earlhumdev.2003.10.007.
We previously reported decreases in fetal heart rate (FHR) variability and body and breathing movements after maternal betamethasone administration. We now test the hypothesis that fetal responsiveness to betamethasone depends on the gestational age at which glucocorticoid therapy is started.
1-h recordings of FHR (n=350) and fetal movements (n=310) made during a 5-day period (days 0-4) were available for analysis. The recordings had been obtained from 63 pregnant women at high risk for preterm delivery who received betamethasone (two doses of 12 mg 24 h apart) between 26 and 34 weeks' gestational age (wGA). The response to betamethasone, i.e. the direction and magnitude of change in FHR and movement parameters compared with baseline (day 0), was studied in relation to gestational age at drug administration.
Fetuses exposed to betamethasone at 29-34 wGA showed a decrease in FHR on day 1 (indicative of baroreceptor reflex), and reduced breathing activity and prolonged episodes of quiescence with a concomitant decrease in body movements on days 1 and 2. However, these changes were not observed if betamethasone administration occurred at 26-28 wGA. Betamethasone-induced reductions in FHR variability were similar in young and older fetuses.
Age-related differential responsiveness to betamethasone was found for all studied fetal processes (body and breathing movements, FHR, and quiescence), except FHR variability. Our results suggest ontogenic changes in the mechanisms presumed to underlie these processes (glucocorticoid receptor (GR) maturation, cardiovascular and neuro-endocrine development).
我们之前报道了母体给予倍他米松后胎儿心率(FHR)变异性以及身体和呼吸运动减少。我们现在检验这样一个假设,即胎儿对倍他米松的反应性取决于开始糖皮质激素治疗时的胎龄。
可用于分析在5天期间(第0 - 4天)进行的1小时FHR记录(n = 350)和胎儿运动记录(n = 310)。这些记录来自63名早产高危孕妇,她们在孕龄(wGA)26至34周期间接受了倍他米松(两剂,相隔24小时,每剂12毫克)。研究了与给药时的孕龄相关的对倍他米松的反应,即与基线(第0天)相比FHR和运动参数变化的方向和幅度。
在孕龄29 - 34周时接触倍他米松的胎儿在第1天显示FHR下降(表明压力感受器反射),并且在第1天和第2天呼吸活动减少,安静期延长,同时身体运动减少。然而,如果在孕龄26 - 28周时给予倍他米松,则未观察到这些变化。倍他米松引起的FHR变异性降低在年轻和年长胎儿中相似。
除了FHR变异性外,在所有研究的胎儿过程(身体和呼吸运动、FHR和安静期)中都发现了与年龄相关的对倍他米松的不同反应性。我们的结果表明,推测为这些过程基础的机制(糖皮质激素受体(GR)成熟、心血管和神经内分泌发育)存在个体发育变化。